To learn more about our research disclaimers please visit our page Research-only disclaimer
By engaging growth-factor and nitric-oxide pathways, BPC-157 offers a versatile platform for studying tissue dynamics in skin, gut, and nervous-system models
In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases
If appropriate, youll receive a personalized injection schedule and medication shipped to you.
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
"Not all that is red is blood: a curious case of chromaturia"